Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.66 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.66 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615490 | 0.90 | ENPP2 (0.71) | LPLLIPGENPP2CA1CA2 | |
| SCHEMBL20278668 | 0.84 | LPL (0.67) | LPLLIPGENPP2CA1CA2 | |
| SCHEMBL3138179 | 0.81 | LPL (0.90) | LPLLIPGENPP2CA1CA2 | |
| SCHEMBL12932655 | 0.81 | ENPP2 (0.57) | LPLLIPGENPP2CA1CA2 | |
| SCHEMBL12215760 | 0.80 | LPL (0.56) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL1997891 | 0.79 | LIPG (1.00) | LPLLIPGENPP2CA1CA2 | |
| SCHEMBL29951479 | 0.79 | ENPP2 (0.49) | LPLLIPGENPP2 | |
| SCHEMBL8528 | 0.79 | ENPP2 (0.61) | LPLLIPGENPP2CA1CA2 | |
| SCHEMBL202958 | 0.79 | LPL (0.69) | LPLLIPGENPP2CA1CA2 | |
| SCHEMBL18486275 | 0.78 | LPL (0.59) | LPLLIPGENPP2NLRP3CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | LPL 474/4885LIPG 103/4885ENPP2 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.